Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Buffa R, Capella C, Fontana P, Usellini L, Solcia E
With an additional change of the CGFS signature to CSYC, reduction of roGFP2 increased only slightly (approximately to 1.8% of class I HsGRX2), but HED activity was increased more efficiently (approximately to 2.5% of class I HsGRX2) 14
However, recognised risks like pancreatitis and gallbladder disease can present with pain radiating to the back
2024;16(8):e67459
US$ 24.48
US$ 24.02
US$ 26.94
US$ 20.52
US$ 26.01
US$ 24.05
